

Hadean Capital I AS and HVentures Capital I AB Periodic Disclosure

Pursuant to Article 11 of Regulation (EU) 2019/2088 (“SFDR”), cf. Article 8, and Annex IV of the Regulatory Technical Standards (the “RTS”)

Product name: Hadean Capital I AS / HVentures Capital I AB (referred to as “the Fund”)

Legal entity identifier: Hadean Capital I AS LEI 549300QZCIA1RGZE2P94 / HVentures Capital I AB LEI 549300J03MX6GC6VSC13

Hadean Capital I AS and HVentures Capital I AB invest in parallel in accordance with the fund agreements, and it is considered appropriate for the funds to share a common periodic disclosure.

Did this product have a sustainable investment objective?	
<input checked="" type="radio"/> <input checked="" type="radio"/> <input type="checkbox"/> Yes	<input checked="" type="radio"/> <input type="radio"/> <input checked="" type="checkbox"/> No
<input type="checkbox"/> It made sustainable investments with an environmental objective: ___ % <ul style="list-style-type: none"> <input type="checkbox"/> In economic activities that qualify as environmentally sustainable under the EU Taxonomy <input type="checkbox"/> In economic activities that do not qualify as environmentally sustainable under the EU Taxonomy <input type="checkbox"/> It made sustainable investments with a social objective: ___ %	<input checked="" type="checkbox"/> It promotes Environmental/Social (E/S) characteristics and while it did not have as its objective a sustainable investment, it has a proportion of: ___ % sustainable investments. <ul style="list-style-type: none"> <input type="checkbox"/> With an environmental objective in economic activities that qualify as environmentally sustainable under the EU Taxonomy <input type="checkbox"/> With an environmental objective in economic activities that do not qualify as environmentally sustainable under the EU Taxonomy. <input type="checkbox"/> With a social objective. <input checked="" type="checkbox"/> It promoted E/S characteristics but did not make any sustainable investments.

1. To what extent were the environmental and/or social characteristics promoted by this financial product met?

Hadean’s and the Funds’ primary goal, and a clear social characteristic, is “to solve global medical challenges, contributing to better health and increased wellbeing”. The investments of the fund contribute to this goal by developing innovative solutions with the potential to address unmet medical needs. Beyond medical challenges, we are committed to fostering positive change by leveraging our influence as owners. Aligned with the UN SDGs, it focuses on various key E/S factors, including good health and well-being, industry, innovation and infrastructure, responsible consumption and production and gender equality. These characteristics are met through exclusionary criteria, due diligence and active ownership.

- **How did the sustainability indicators perform?**

As an active owner, we work with each portfolio company to improve its sustainability efforts, including internal governance mechanisms to ensure sound management and effective oversight. The fund considers principal adverse impacts on sustainability factors (PAIs), which involve identifying and monitoring PAI indicators annually with a commitment to minimizing the adverse impacts of our investments. Additionally, we have identified areas where we believe we can contribute to positive change. Based on this, we have identified four areas where we will prioritize our efforts. These include:

- 1) Better health and well-being by investing in innovative companies addressing unmet medical needs
- 2) Proper handling of hazardous waste through well-established routines and procedures
- 3) Climate change combat through reduction of GHG emissions
- 4) Gender equality and diversity reflected in recruitment processes and pay gap absence

Please find below the prioritized sustainability indicators used to measure the achievement of our overarching goal and E/S characteristics, linked to relevant SDGs and targets:

E/S Characteristics	Sustainability Indicators	Metric	Sustainable Development Goal and Target
Better health and well-being	Proportion of companies that successfully advance to pre-clinical or clinical trials	100%	SDG 3 Good health and well-being, target 3.8 and 3b SDG 9 Industry, Innovation and Infrastructure, target 9.5
Hazardous waste	Proportion of companies reporting hazardous waste	67%	SDG 12 Responsible Consumption and Production, target 12.4 and 12.5
Climate change combat	Proportion of companies that has implemented initiatives to limit carbon footprint	65%	
Gender equality and diversity	Board gender diversity	82%	SDG 5 Gender Equality, target 5.5
	Gender pay gap	28%	
	Gender diversity management team	24%	

2. How did this financial product consider principal adverse impacts on sustainability factors?

Hadean and the Fund consider the principal adverse impacts (PAI) of investment decisions on sustainability factors. PAI indicators are used to identify and mitigate any significant adverse impacts of our investments, and take action as required. In line with Hadean' ESG Policy and SOP, sustainability impacts are assessed prior and post investment. Prior to investment decisions, PAIs are assessed as part of Hadean' ESG due diligence process. If Hadean identifies significant adverse impacts and considers our opportunities to influence improvements as limited, Hadean may abstain from the investment. During ownership, Hadean conduct annual ESG reviews and engage with each portfolio company to improve sustainability efforts and reduce adverse impacts. This involves collecting and monitoring data on all mandatory and two additional PAI indicators. Based on the company's performance, Hadean provides feedback, suggests improvements, and offer support. We also vote on resolutions and propose shareholder resolutions on ESG considerations if we hold a Board seat, and we collaborate with other shareholders to influence portfolio company approaches to ESG when necessary.

For further details, please refer to Hadean's PAI Statement, available on our website.

3. What were the top investments of this financial product?


Largest investments	Sector	% Asset	Country
Abliva AB	Drug development	22%	Sweden
Oncoinvent	Drug development	13%	Norway
Saga Diagnostics	Diagnostics	12%	Sweden
Step Pharma	Drug development	11%	France
Cardior	Biotech	11%	Germany
Contineum Therapeutics	Drug development	10%	USA

The Fund was launched in 2017 and holds 10 investments. The above table only includes % asset of invested amount. The majority of the companies in the portfolio are at the Series A stage.

4. What was the proportion of sustainability-related investments?

The Fund exclusively targets companies dedicated to solving unmet medical needs. This ensures that every investment contributes to achieving E/S characteristics, without any minimum allocation requirement. None of the investments fall under the sustainable investment definition outlined in Article 2 of the SFDR. Moreover, the Fund has solely engaged in direct investments in portfolio companies.

- What was the asset allocation?



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

- In which economic sectors were the investments made?

Investments	Sector	NACE Codes
Abliva AB	Drug development	72.19 - Other research and experimental development on natural sciences and engineering.
Oncoinvent	Drug development	72.19 - Other research and experimental development on natural sciences and engineering.
Saga Diagnostics	Diagnostics	72.19 - Other research and experimental development on natural sciences and engineering.

Step Pharma	Drug development	72.19 - Other research and experimental development on natural sciences and engineering.
Cardior	Biotechnology	72.11 - Research and experimental development on biotechnology 72.19 - Other research and experimental development on natural sciences and engineering.
Contineum Therapeutics	Drug development	72.19 - Other research and experimental development on natural sciences and engineering.

5. What investments were included under “other”, what was their purpose and were there any minimum environmental or social safeguards?

No investments under “other”. All investments promote E/S characteristics.

6. What actions have been taken to meet the environmental and/or social characteristics during the reference period?

- **Focused Investments:** The fund exclusively made investments that fulfilled the criteria of addressing a medical unmet need.
- **Due Diligence:** Hadean conducted ESG due diligence for all potential investments, as outlined in the Website Disclosure and the Principal Adverse Impact Statement.
- **Data collection and monitoring:** We collected ESG data and monitored progress. We supported portfolio companies with access to experts, tools and resources, including support with implementing internal governance mechanisms and policy frameworks.
- **Board participation and voting:** We formally expressed approval or disapproval through voting on resolutions and proposed shareholder resolutions on specific ESG considerations.
- **Dialogue and cooperation:** We provided feedback and suggested improvements on material ESG matters. We collaborated with other shareholders to influence how ESG considerations should be addressed by the portfolio company.
- **Management of conflicts of interest:** We monitored actions and transactions for potential conflicts between the portfolio manager and the portfolio company. No such conflicts were identified.